Trending Now
Could Carbon Markets be approaching a Trillion-Dollar Valuation?
One of the most highly sought-after investment themes since the tech boom in the late 90s might be a sector to which...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Applied Genetic Technologies Corporation (NASDAQ: AGTC) Announce Interim Results of Ongoing...
Applied Genetic Technologies Corporation (NASDAQ: AGTC) has reported interim three-month paediatric data and further adult safety findings to almost 24 months from the ongoing...
MAKE IT MODERN
LATEST REVIEWS
Atossa Therapeutics Inc (NASDAQ:ATOS) Reports Tolerability And Safety Of AT-301 In...
Atossa Therapeutics Inc (NASDAQ:ATOS) reported positive results from the Phase 1 clinical trial of its innovative drug candidate AT-301. Currently, no FDA-approved treatments are...
MAKE IT MODERN
PERFORMANCE TRAINING
Epizyme Inc. (NASDAQ:EPZM) Receives FDA Approval For TAZVERIK sNDA In Two Folicular Lymphoma Indications
Epizyme Inc. (NASDAQ:EPZM) has announced that its drug TAZVERIK (tazemetostat) has received FDA approval for supplemental New Drug Application for two distinct follicular lymphoma...
Viracta Therapeutics Inc. (NASDAQ: VIRX) Receives Orphan Drug Designation For Oral Combination Of Nanatinosta...
Viracta Therapeutics Inc. (NASDAQ: VIRX) has announced that the FDA has awarded its all-oral combination drug candidate nanatinostta and valganciclovir orphan drug designation for...
Akebia Therapeutics Inc (NASDAQ:AKBA) Will Post Q1 2021 Revenues On May 10, 2021: NEJM...
Akebia Therapeutics Inc (NASDAQ:AKBA) will release Q1 2021 earnings on May 10, 2021. It will host a conference call on the same day at...
Celldex Therapeutics Inc. (NASDAQ:CLDX) Announce Encouraging CDX-0159 Study Results In Reducing Plasma Tryptase
Celldex Therapeutics Inc. (NASDAQ:CLDX) has announced results from its first phase, double-blind, randomized, placebo-controlled, dose-escalation KIT inhibitor CDX-0159 study in healthy subjects.
CDX-0159 shows a...
Sesen Bion (NASDAQ: SESN) Completes Vicineum Commercialization Plans Ahead Of Approval
Sesen Bion (NASDAQ: SESN) has announced the completion of its marketing planning ahead of the expected Vicineum launch in the US once approved. Equally,...
MAKE IT MODERN
